Harmony Biosciences Holdings, Inc.

Harmony Biosciences Holdings, Inc.

HRMY·NASDAQ

$32.79

+2.1%
HealthcareBiotechnology

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.

At a Glance

Live Snapshot
Market Cap$1.90B
EPS2.7600
P/E Ratio11.88
Earnings Date08/04/2026

hrmy

Research Development Expenses

Last Annual Value

189.59M

3-Year CAGR

39%

5-Year CAGR

58%

10-Year CAGR

31%

Harmony Biosciences Holdings, Inc.

Harmony Biosciences Holdings, Inc. Competitors Analysis of research-development-expenses

HRMY · NASDAQ
Companyresearch-development-expenses
CAGR 3Y
CAGR 5Y
CAGR 10Y
189.59M
35.6%44.2%N/A 
66.35M
28.5%40.1%16.1%
BHVN logo
Biohaven Ltd.
NYSE:BHVN
635.07M
19.4%28.5%N/A
60.26M
14.0%N/AN/A
245.10M
27.6%34.0%9.1%
125.90M
31.9%36.8%N/A
115.11M
17.3%10.8%N/A
215.26M
40.1%57.1%N/A
Harmony Biosciences Holdings, Inc.

Harmony Biosciences Holdings, Inc. Fair Value Envelope

HRMY · NASDAQ

Our analysis suggests that HRMY has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $32.79, this represents a potential HIDDEN relative to our calculated worth for Harmony Biosciences Holdings, Inc..

Intrinsic Value
Current Price: $32.79